Patient population
Myasthenia Gravis
MUSCLE WEAKNESS, MYASTHENIA GRAVIS
Inclusion criteria included participants ≥ 18 years of age with a diagnosis of MG with generalized muscle weakness, diagnosed as Myasthenia Gravis Foundation of America class II to IV, with an MG-ADL total score ≥ 5 points (> 50% of score attributed to nonocular symptoms), and on a stable dose of ≥ 1 gMG treatment prior to screening and throughout the study [